Researchers from Aarhus University have for the first time linked a new protein with malignant melanomas; the protein is detected in aggressive malignant melanoma cells and might be used to predict whether and how the cancer will spread
MRV Research
Triple combination of two targeted therapies + immunotherapy is more effective in advanced melanoma
A groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combinations alone. The triple combination has increased immune response and fewer side effects. It was described in Science Translational Medicine
Melanoma Epigenetic Regulators Underlie Melanoma Progression and Therapy-Resistance
In a new study entitled “Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state,” a research team at University of Leuven in Belgium reported two novel master regulators that render melanoma cells capable of invading and metastasizing to different body parts, while promoting their resistance to current clinical therapeutics. The study was published in the journal Nature Communications.
Adjuvant ipilimumab prolongs RFS in stage III melanoma
NEW YORK — Patients with high-risk stage III melanoma who received ipilimumab after complete resection demonstrated prolonged RFS compared with patients who received placebo, according to phase 3 study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.